| Schedule of Disaggregation of Revenue |
The table below illustrates net sales by segment and division and by market geography for fiscal years 2026, 2025, and 2024. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries. | | | | | | | | | | | | | | | | | | | | Worldwide | | Fiscal Year | | (in millions) | 2026 | | 2025 | | 2024 | | Cardiac Rhythm & Heart Failure | $ | 7,504 | | | $ | 6,392 | | | $ | 5,995 | | | Structural Heart & Aortic | 3,817 | | | 3,554 | | | 3,358 | | | Coronary & Peripheral Vascular | 2,656 | | | 2,535 | | | 2,478 | | | Cardiovascular | 13,976 | | | 12,481 | | | 11,831 | | | Cranial & Spinal Technologies | 5,222 | | | 4,973 | | | 4,756 | | | Specialty Therapies | 2,997 | | | 2,940 | | | 2,905 | | | Neuromodulation | 2,068 | | | 1,932 | | | 1,746 | | | Neuroscience | 10,287 | | | 9,846 | | | 9,406 | | | Surgical & Endoscopy | 6,764 | | | 6,498 | | | 6,508 | | | Acute Care & Monitoring | 2,051 | | | 1,909 | | | 1,908 | | | Medical Surgical | 8,815 | | | 8,407 | | | 8,417 | | | Reportable segment net sales | 33,079 | | | 30,734 | | | 29,654 | | | Diabetes | 3,112 | | | 2,755 | | | 2,488 | | Other operating segment(1) | 135 | | | 137 | | | 221 | | Other adjustments(2) | 39 | | | (90) | | | — | | | Total net sales | $ | 36,364 | | | $ | 33,537 | | | $ | 32,364 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | U.S. | | International | | Fiscal Year | | (in millions) | 2026 | | 2025 | | 2024 | | 2026 | | 2025 | | 2024 | | Cardiovascular | $ | 6,435 | | | $ | 5,804 | | | $ | 5,597 | | | $ | 7,541 | | | $ | 6,677 | | | $ | 6,234 | | | Neuroscience | 6,875 | | | 6,713 | | | 6,305 | | | 3,412 | | | 3,133 | | | 3,101 | | | Medical Surgical | 3,778 | | | 3,664 | | | 3,717 | | | 5,037 | | | 4,744 | | | 4,700 | | | Reportable segment net sales | 17,088 | | | 16,181 | | | 15,619 | | | 15,991 | | | 14,553 | | | 14,035 | | | Diabetes | 934 | | | 923 | | | 852 | | | 2,178 | | | 1,832 | | | 1,636 | | Other operating segment(1) | 81 | | | 68 | | | 91 | | | 54 | | | 70 | | | 131 | | Other adjustments(2) | — | | | — | | | — | | | 39 | | | (90) | | | — | | | Total net sales | $ | 18,103 | | | $ | 17,171 | | | $ | 16,562 | | | $ | 18,261 | | | $ | 16,365 | | | $ | 15,802 | |
(1)Includes operations and ongoing transition agreements from businesses the Company has exited or divested. (2)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.
|